Please assess the completion status of the following clinical trial:

Trial Title: A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* male,and post-menopausal or surgically sterilized female, patients, 18-75 years of age;~* type 2 diabetes mellitus, with stable metformin treatment for \>=3 months;~* HbA1c \>=7.0% and \<=9.5% at screening;~* stable weight +/-10% for \>=3 months before screening.~Exclusion Criteria:~* type 1 diabetes mellitus;~* clinically significant gastrointestinal disease;~* treatment with any anti-hyperglycemic medication other than metformin monotherapy during last 3 months;~* use of weight-lowering medications in the last 3 months;~* uncontrolled hypertension;~* previous exposure to GLP-1 or GLP-1 analogues.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): sc weekly
- Taspoglutide 20mg (Type: EXPERIMENTAL): sc weekly
- Taspoglutide 20mg-30mg (Type: EXPERIMENTAL): sc weekly
- Taspoglutide 20mg-40mg (Type: EXPERIMENTAL): sc weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).